Back to Search
Start Over
Lipoprotein apheresis reduces major adverse cardiovascular event incidence in high-lipoprotein (a) subjects on proprotein convertase subtilisin/kexin type 9 inhibitor therapy.
- Source :
-
European journal of preventive cardiology [Eur J Prev Cardiol] 2024 Jun 03; Vol. 31 (8), pp. e62-e64. - Publication Year :
- 2024
-
Abstract
- Competing Interests: Conflict of interest: none declared.
- Subjects :
- Humans
Incidence
Male
Female
Middle Aged
Biomarkers blood
Treatment Outcome
Serine Proteinase Inhibitors therapeutic use
Serine Proteinase Inhibitors adverse effects
Aged
Hyperlipoproteinemias blood
Hyperlipoproteinemias therapy
Hyperlipoproteinemias complications
Hyperlipoproteinemias epidemiology
Hyperlipoproteinemias drug therapy
Hyperlipoproteinemias diagnosis
Proprotein Convertase 9 metabolism
PCSK9 Inhibitors
Lipoprotein(a) blood
Blood Component Removal adverse effects
Cardiovascular Diseases prevention & control
Cardiovascular Diseases epidemiology
Cardiovascular Diseases blood
Subjects
Details
- Language :
- English
- ISSN :
- 2047-4881
- Volume :
- 31
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- European journal of preventive cardiology
- Publication Type :
- Academic Journal
- Accession number :
- 38470832
- Full Text :
- https://doi.org/10.1093/eurjpc/zwae054